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Abstract
Purpose: The purpose of this article is to educate nurse practitioners about
the pathophysiology surrounding the development of portal hypertension and
the effective use of nonselective ß-blockers to prevent primary bleeding and
decrease the mortality risk.
Data sources: The articles included were retrieved via ISI Web of Science
using the years 2004–2009 and key words cirrhosis, portal hypertension,
esophageal varices, and beta-blockers. This information included scholarly
books, journal reviews, retrospective chart reviews, and prospective random-
ized studies.
Conclusions: Cirrhosis is the leading cause of portal hypertension in Europe
and North America. Esophageal varices are a result of the portosystemic col-
laterals the body develops to decompress the portal system. Hemorrhage from
esophageal varices is a major cause of morbidity and mortality. Prevention of
a primary bleed is the goal of therapy and is accomplished with nonselective
ß-blockers.
Implications for practice: Very few patients with portal hypertension and
esophageal varices are on ß-blockers. Use of nonselective ß-blockers has
been found to lower portal pressure and decreases the risk of bleeding from
esophageal varices and therefore decreases mortality. Patients unable to use
ß-blockers can undergo endoscopic variceal ligation as an alternate method to
reduce risk of bleeding.
Patients with portal hypertension are at an increased risk
of developing esophageal varices. In Europe and North
America, cirrhosis accounts for 90% of the cases of por-
tal hypertension (Triantos & Burroughs, 2007). Other
causes can include thrombosis of any of the veins lead-
ing to the liver (portal, superior mesenteric, or splenic),
idiopathic portal hypertension, primary biliary cirrhosis,
primary sclerosing cholangitis, vitamin A toxicity, inﬁltra-
tive disorders, veno-occlusive disease, Budd-Chiari syn-
drome, and congestive heart failure (Toubia & Sanyal,
2008).
Esophageal varices are a major concern in patients
with cirrhosis. These varices have a high propensity to
bleed because of the fragility of the engorged blood
vessels (Cichoz-Lach, Celinski, Slomka & Kasztelan-
Szczerbinska, 2008). Each episode of bleeding has a
30%–50% mortality risk. Furthermore, after the initial
episode of bleeding the incidence of rebleeding is up to
70% and frequently occurs within 6 weeks of the initial
hemorrhage (Sharma & Rakela, 2005; Toubia & Sanyal,
2008).
For patients with esophageal varices the goal of treat-
ment is to reduce portal hypertension. By reducing portal
pressure there is a concomitant decrease in the probabil-
ity of esophageal bleeding. Reducing the risk of primary
bleeding of esophageal varices can be accomplished by us-
ing nonselective ß-blocker therapy. This pharmacological
intervention works by reducing the hepatic venous pres-
sure gradient (HVPG). The HPVG is a measure of the pres-
sure difference in the portal vein and the intra-abdominal
portion of inferior vena cava and is typically between 5
and 10 mmHg (Toubia & Sanyal, 2008).
Unfortunately, many patients with portal hyperten-
sion are not receiving ß-blocker therapy or are not on
doses adequate to attain therapeutic results. The rea-
sons include: therapy is never initiated, the dose is not
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therapeutic, or the patient or the healthcare provider dis-
continues ß-blockers because of the side effects.
Even with treatment of nonselective ß-blocker therapy
only 38% of patients respond (Sharma, Kumar, Sharma
& Sarin, 2009). At present there is no way to identify
who will be a responder unless the invasive method
of HVPG measurement is used. Instead, adequate end-
points of ß-blocker therapy are monitored noninvasively
by heart rate and blood pressure reduction. While this
is not always an indication of being a responder, it is
easy, noninvasive, and the most accepted method to
date.
In spite of the documented need to reduce heart rate by
20%–25% with ß-blocker therapy, healthcare providers
are not reaching this endpoint or just not prescribing the
medications. There is a knowledge deﬁcit related to the
need to use this pharmacological intervention. Therefore,
this is an area in which nurse practitioners (NPs) can
make great strides. By starting the patient on ß-blocker
therapy and monitoring closely for side effects, NPs can
adjust dosages and provide encouragement for patients
to “stay the course” and let their body adapt to the treat-
ment regimen.
Pathophysiology
The normal HVPG is typically 5–10 mmHg. The risk of
developing esophageal varices increases when the HVPG
reaches a minimum pressure of 10–12 mmHg (Toubia &
Sanyal, 2008). Portal hypertension, as measured by the
HVPG, occurs through complex physiological responses
resulting in both mechanical and dynamic blockages in
the liver (Dib et al., 2006). The mechanical component
of blockage is a result of intrahepatic ﬁbrosis starting at
the level of hepatic microcirculation. The ﬁbrosis devel-
ops because of damage to hepatocytes occurring as a re-
sult of alcohol or other liver-damaging processes. Fibro-
blast and activated hepatic stellate cells appear at the area
of injury and deposit collagen. This process leads to con-
nective tissue formation in the periportal and pericentral
zones of the liver. These spiderweb-like tissue formations
eventually connect the portal triads and central veins of
the liver. Also, these areas of ﬁne connective tissue sur-
round small groups of liver cells and, in turn, cause regen-
eration of the liver cells with resulting nodule formation.
This mechanical process causes hardening of the tissue
and nodule formation within the liver and initiates the
blockage of circulatory pathways (Kasper et al., 2005).
The second component involved in portal hyperten-
sion is dynamic blockage. This process occurs as a result
of inappropriate vasoconstriction and vasodilation within
the portal system. Vasoconstriction occurs because of the
inappropriate contraction of portal and septal myoﬁbro-
blasts, hepatic stellate cells, and vascular smooth mus-
cle cells. This takes place through an assortment of vaso-
constrictors being activated when damage occurs to the
hepatocytes. The vasoconstrictors involved include nor-
epinephrine, endothelin, angiotension II, leukotrienes,
and thromboxane A2 (Dib et al., 2006). As these vasocon-
strictors become both overproductive and hyperrespon-
sive as a result of the damage to the hepatocytes, pres-
sure within the portal system increases to levels that can
induce the development of esophageal varices (Cichoz-
Lach et al., 2008). This dynamic component is further
compounded by the activation of vasodilators, such as ni-
tric oxide, which increase the portal vascular congestion
through increased blood ﬂow. This portion of the hyper-
kinetic circulation develops because of the nitric oxide
increasing the cardiac output and promoting pervasive
vasodilation of the vascular bed. Finally, as a result of
the increased dynamic blood ﬂow there is constant shear
stress in the vascular structures that leads to vascu-
lar remodeling. The mechanical and dynamic blockage
processes lead to a continuing cycle that contributes to
the increase in portal hypertension (Cichoz-Lach et al.,
2008).
The sequela of this entire process is esophageal varices.
Varices form as a result of the body’s effort to decompress
the portal vein and return blood to the systemic circula-
tory system. The body achieves this through development
of portosystemic venous collaterals that can form at many
sites. These sites include the rectum, umbilicus, retroperi-
toneum, and the distal esophagus and proximal stomach.
While other sites of collateral circulation can develop,
most patients will develop gastroesophageal varices be-
cause this allows for the largest collateral ﬂow via the
short and left gastric veins (Toubia & Sanyal, 2008). In
fact, of patients with portal hypertension an overwhelm-
ing majority, approximately 80%–90%, will develop gas-
troesophageal varices (Cichoz-Lach et al., 2008).
Diagnosis
Patients suspected of having cirrhosis are deﬁnitively
diagnosed by liver biopsy. This is considered the gold
standard for determining the presence and severity of
necroinﬂammatory activity and ﬁbrosis (Thuluvath &
Krok, 2005). After conﬁrming cirrhosis, the best method
to identify esophageal varices is via upper endoscopy. This
technique provides direct visualization of the esophagus
and stomach and, if varices are present, the ability to de-
termine their size and appearance. It also allows for in-
terventional treatment such as endoscopic variceal liga-
tion (EVL) if the varices are large and the patient is not a
candidate for ß-blocker therapy (Toubia & Sanyal, 2008;
Triantos & Burroughs, 2007).
641Beta-blocker therapy for esophageal varices T. Tursi
Figure 1 Variceal appearance on endoscopy ("red signs"): red wale
marks (longitudinal red streaks on varices); cherry-red spots (red, dis-
crete, ﬂat spots on varices); hematocystic spots (red, discrete, raised
spots); diffuse erythema ( Murra-Saca, 2009).
At present, upper endoscopy is the gold standard to di-
agnose varices. In the future, a multidetector computed
tomography (CT) esophagography could be an option to
evaluate for varices in a less invasive manner. The ma-
jor drawbacks to CT at this time include lack of ability to
perform therapeutic intervention if needed at the time of
evaluation, inability to assess the qualitative endoscopic
appearance, such as red signs (Figures 1 and 2), and an
increased risk of radiation exposure as compared to rou-
tine CT examination (Kim et al., 2007).
When esophageal varices are present it is imperative
to categorize their appearance. Currently, there are two
accepted methods to describe varices. One method is that
of the Japanese Research Society for Portal Hypertension,
which describes them by red color signs, the color of the
varix, the form (size), and the location (Toubia & Sanyal,
Figure2 Esophagealvarices.Exampleofesophagealvarices(Murra-Saca,
2009).
2008). The second method is described by the North-
ern Italian Endoscopy Club and identiﬁes them as F1,
F2, or F3, with this identiﬁcation system corresponding
with small, medium, and large. It also identiﬁes any red
marks on the varices (Toubia & Sanyal, 2008). Whichever
method is used, it is important to understand the basic
premise that the larger the varices the greater the propen-
sity to bleed.
Both methods provide for the recognition of red marks.
The red sign can be described as red wale marks that are
longitudinal red streaks on the varix. Cherry red spots are
another common occurrence on varices. These are red,
discrete, ﬂat spots on the varices. The presence of either
of these can be viewed as an ominous sign indicating an
increased risk of bleeding from varices (Toubia & Sanyal,
2008).
Screening for varices should be initiated when a patient
is diagnosed with cirrhosis. In cirrhotic patients there is
a 5%–15% chance per year of developing varices. Af-
ter varices appear, they will increase in size 4%–10%
annually (Toubia & Sanyal, 2008). If the initial en-
doscopy reveals no varices, screening can be performed
every 3 years. For those patients who have small varices,
screening should be performed every 2 years. However,
if large varices are found there is no need to do follow-up
endoscopy. Instead, primary prophylaxis should be initi-
ated immediately with nonselective ß-blocker therapy if
there are no contraindications such as bronchial asthma,
hypotension, bradycardia, 2nd or 3rd degree heart block,
or chronic obstructive pulmonary disease (COPD; Dib
et al., 2006). In patients with large varices who are started
on ß-blockers, posttreatment endoscopy is not performed
because the risk of a variceal bleed outweighs the ben-
eﬁt of the procedure. Repeat endoscopy would only be
performed in the setting of hemorrhage from esophageal
varices.
For patients with contraindications to ß-blocker ther-
apy, or considered at high risk for noncompliance with
the medication regimen, EVL would be the secondary
treatment option. EVL is the second line therapy because
there is a risk of bleeding from the varices postprocedure.
See Figure 3 for a suggested approach to management.
It is interesting to note that studies do not show any
beneﬁt in starting ß-blocker therapy prior to the devel-
opment of varices because it does not prevent them from
forming. However, some studies do advocate starting ß-
blocker therapy when small varices develop to help slow
progression (Triantos & Burroughs, 2007). More studies
need to be conducted to validate this ﬁnding.
In addition to concern about esophageal varices, it is
important to note there are other sequelae of portal hy-
pertension. There can be a rise in serum bilirubin with as-
sociated jaundice; this is a hallmark sign of end stage liver
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Upper
endoscopy
No Varices  Small
varices
Medium to 
large varices 
Monitor
with EGD 
every 3 
years
Monitor
with EGD 
every 2 
Portal Hypertension 
No Yes
Contraindications to ß-blockers? 
(hypotension, bradycardia, 2
nd/3
rd
degree heart block, bronchial 
asthma, COPD) 
No Yes
Start nonselective
ß-blocker therapy 
(nadolol or 
propranolol)
Proceed
with EVL 
Teaching and 
monitoring to 
decrease
further liver 
damage
Figure 3 Management of varices: EGD,
esophogastroduodenoscopy; EVL, endoscopic
variceal ligation.
disease (ESLD). The serum albumin will also decrease in
patients with portal hypertension because albumin is syn-
thesized solely by hepatocytes. Moreover, hepatocytes are
responsible for the production of blood clotting factors.
As the number of functioning hepatocytes decrease, the
prothrombin time elevates. Ascites can also be a physical
ﬁnding in patients with portal hypertension. The cause
is unclear but one theory is the sequestration of ﬂuid in
the splanchnic vascular bed leads to decreases in effec-
tive circulating volume. This triggers the kidneys to re-
tain salt and water. The hypoalbuminemia and reduced
plasma oncotic pressure then increase the incidence of
extravasation of ﬂuid into the peritoneal cavity. Another
result of portal hypertension is the development of hep-
atic encephalopathy. While the cause is unknown, it is
theorized that it is related to various toxic substances be-
ing absorbed from the intestinal tract, but not detoxiﬁed
by the liver (Kasper et al., 2005).
As part of the evaluation and management of cirrho-
sis and portal hypertension, it is important to stage this
disease process with the Child-Pugh score. This scoring
method can assist in identifying those at higher risk for
major complications such as esophageal varices. Calcu-
lation of a Child-Pugh score is done by assessment of
serum bilirubin level, serum albumin level, prothrom-
bin time, presence or absence of ascites, and hepatic en-
cephalopathy (Table 1). Based on the scores, patients are
placed in Category A (5–6 points), B (7–9 points), or C
(10–15 points), with the higher scores indicating a more
advanced state of disease and higher risk of major com-
plications (Kasper et al., 2005).
Management
In treating patients with esophageal varices the
goal of therapy is primary prevention of bleeding.
At present there are two options available. The ﬁrst
line treatment is pharmacological intervention with
nonselective ß-blocker therapy. The second treatment
option available, if there are contraindications to non-
selective ß-blockers, is EVL. In using EVL it is important
to note it is only used with medium to large varices be-
cause the risk of bleeding with EVL post treatment out-
weighs the beneﬁt in treatment of smaller varices.
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Table 1 Child-Pugh score
Factor Unit 1 point 2 points 3 points
Serum bilirubin μmole/L <34 34–51 >51
mg/dL <2.0 2.0–3.0 >3.0
Serum albumin g/L >35 30–35 <30
g/dL >3.5 3.0–3.5 <3.0
Prothrombin time Second Prolonged INR 0–4 4–6 >6
<1.7 1.7–2.3 >2.3
Ascites None Easily controlled Poorly controlled
Hepatic encephalopathy None Minimal Advanced
Note.Addscoresfromtheﬁvefactors.Child-Pughscoresare:classA(scoreof5–6),B(7–9),orC(10orabove).IfChild-PughScoreis7ormoreinpatients
with cirrhosis, it is an indication of decompensation (Kasper et al., 2005). INR = international normalized ratio.
Nonselective ß-blockers have been shown to lower
the HVPG. The median reduction of the HVPG with
nonselective ß-blocker therapy is 15%. Some studies
have presented evidence that bleeding of esophageal
varices generally does not occur until the pressure gra-
dient is more than 12 mmHg. Therefore, even a mod-
est reduction of 15% can potentially reduce HVPG from
12 to 10.2 mmHg, thus greatly reducing the risk of
bleeding (Dib et al., 2006). In fact, treatment with non-
selective ß-blocker therapy shows evidence of reducing
the risk of primary bleeding of esophageal varices by up
to 50%. Along with decreasing the risk of bleeding comes
a reduction in mortality by 25%–45% when compared
to no therapeutic intervention (Thuluvath, Maheshwari,
Jagannath, & Arepally, 2005). Meta-analyses also support
these results by showing a 40% decrease in bleeding risk
in patients with whom nonselective ß-blocker therapy is
used (Wilbur & Sidhu, 2005).
Nonselective ß-blockers work by reducing portal blood
ﬂow. This occurs through decreased cardiac output and
decreased azygous blood ﬂow as a result of ß-1 receptor
blockade. Vasoconstriction occurs because of unopposed
alpha vasoconstriction effect which leads to arteriolar
splanchnic vasoconstriction. This physiological response
to the nonselective ß-blocker therapy leads to less blood
ﬂow into the portal system (Dib et al., 2006; Wilbur &
Sidhu, 2005). Use of other ß-blockers, such as atenolol or
metoprolol, do not cause splanchnic vasoconstriction and
therefore would not reduce portal blood ﬂow and portal
pressure (Wilbur & Sidhu, 2005).
Interestingly, it has been noted by Toubia and Sanyal
(2008) that bacteremia is often present in patients admit-
ted for acute variceal hemorrhage. A study conducted by
Perez-Paramo et al. (2000) examined cirrhotic rats with
ascites and found that use of propranolol decreased the
rate of bacterial translocation. In this study the intesti-
nal overgrowth was associated with intestinal hypomotil-
ity. Propranolol accelerated the intestinal transit and de-
creased the rate of bacterial overgrowth. This led to less
translocation of bacteria. This type of effect becomes es-
pecially important in human patients with ascites because
it could reduce the risk of spontaneous bacterial peritoni-
tis, another major health concern in patients with por-
tal hypertension (Dib, Oberti & Cales, 2006). Patients at
risk for spontaneous bacterial peritonitis can be identiﬁed
through the Child-Pugh score.
In a study conducted by Lay et al. (2006), which exam-
ined the use of nonselective ß-blocker therapy as com-
pared to EVL in lowering the risk of a primary bleed, the
target heart rate was aimed at a 20% reduction of the
resting heart rate. Their study protocol used propranolol
s t a r t e da t4 0m gt w i c ead a ya n dt i t r a t e du pb y1 0m g
twice a day to obtain the goal heart rate. Other stud-
ies comparing nonselective ß-blocker therapy and EVL,
such as that of Lo et al. (2004), used nadolol with the
goal of a 25% reduction in heart rate or to decrease heart
rate to 55 beats per minute. Both nonselective ß-blocker
therapy and EVL were effective in decreasing the inci-
dence of hemorrhage of esophageal varices and mortality
associated with hemorrhage. Lo et al. (2004) reported a
bleeding rate at 2 years of 10% (EVL) and 18% (non-
selective ß-blocker therapy) and a 2-year mortality rate
of 22% (EVL) and 24% (nonselective ß-blocker ther-
apy). Lay et al. (2006) found similar ﬁndings with risk
of bleeding at 2 years of 19.2% (EVL) and 16.9% (non-
selective ß-blocker therapy) and mortality at 2 years of
28% (EVL) and 24% (nonselective ß-blocker therapy).
Whether nadolol or propranolol is used is at the discre-
tion of the NP. The main goal is that NPs understand the
importance of the medication and prescribe and monitor
the medications appropriately.
Medication noncompliance with ß-blocker therapy will
be a major concern with most patients. The side effects
include fatigue, dizziness, impotence, dry mouth, nau-
sea, vomiting, diarrhea, and constipation. Education will
be crucial in helping patients stay on the medication. If
644T. Tursi Beta-blocker therapy for esophageal varices
patients understand that their body will adjust and the
side effects will wane, they will be more likely to con-
tinue medication therapy.
Patient education should include instruction on how to
monitor the heart rate. The easiest method for patients is
to use the second and third ﬁngers of one hand to feel
for the radial pulse on the opposite wrist area. Instruct
patients to count the pulse for 30 s and then multiply by
2 for their heart rate per minute. Patients should monitor
their heart rate before each dose of ß-blocker medication
with a target heart rate of 55 beats per minute. If their
heart rate is below this rate they should hold the dose
and call for further instructions. Frequent monitoring of
heart rate and slow titration of the medication will allow
patients time to adapt to the therapy and be more likely
to continue on ß-blocker treatment.
In cases where patients are already on ß-blockers (i.e.,
metoprolol or carvedilol) for treatment of heart failure,
the medical teams will need to decide if switching to
nonselective ß-blocker therapy is a viable option. The
decision must be based on which health concern, heart
failure or portal hypertension, is of greater need. The ß-
blockers used for heart failure will not have the desired
effect of reducing portal blood ﬂow. Likewise, the non-
selective ß-blocker therapy used for portal hypertension
will not have the desired effect on heart failure patients
of helping to improve cardiac function and reduce mor-
tality. When patients are on ß-blockers for other reasons
than heart failure (such as hypertension, angina, arrhyth-
mias, or myocardial infarction) there is less concern about
switching medications to nonselective ß-blocker therapy
because similar effects are attained.
EVL is a treatment option available for patients who are
not candidates for nonselective ß-blocker therapy. Con-
traindications for ß-blocker therapy include bronchial
asthma, hypotension, bradycardia, 2nd or 3rd degree
heart block, or COPD (Dib et al., 2006; Krige, Shaw,
& Bornman, 2005). Additionally, EVL is also the treat-
ment option for patients who are noncompliant with the
medication regimen or those patients who experience
an esophageal variceal bleed despite ß-blocker therapy.
EVL is a moderately invasive procedure that places rub-
ber bands on esophageal varices during upper endoscopy.
First the varices are identiﬁed and then a special device is
used to suck the varix into a cylindrical tube and a rub-
ber band is released to effectively strangle the varix. The
varix will become necrotic and slough off, with the rubber
band, over the course of a week (Krige et al., 2005). EVL
is used prophylactically only on medium to large varices.
In comparison of nonselective ß-blocker therapy and
EVL in the prevention of primary bleeding, both have
been found to be effective in reducing primary bleed rate.
Moreover, there does not appear to be a mortality beneﬁt
between the two. However, some studies report EVL as
the cause for bleeding of varices post banding (Toubia &
Sanyal, 2008), and therefore EVL is considered the alter-
nate choice after pharmacological therapy with nonselec-
tive ß-blocker therapy.
As the ﬁnal part of management of portal hypertension,
patient teaching should include self-monitoring for signs
of bleeding. Occult bleeding can happen as a result of por-
tal gastropathy. Patients may notice the passage of dark,
tarry stools or melena. Also, bleeding can occur from a
less obvious site of varices in portal hypertension, such
as rectal varices. Rectal varices can result in passage of
maroon (hematochezia), or bright red blood per rectum.
Patients should be encouraged to report increasing fa-
tigue, dizziness, syncope, or chest pain. All of these could
be an indication of bleeding. Patient teaching should in-
clude instruction on the use of guaiac smear tests. These
simple test cards can be prepared at home by placing a
smear of stool on each window of the test card and then
sending it to the ofﬁce for evaluation. Also, with each of-
ﬁce visit a simple guaiac test can be performed as part of
the visit protocol. This will serve as another opportunity
to detect occult bleeding.
Implications for practice
Patients with cirrhosis or those with known por-
tal hypertension from other disease states should be
screened for esophageal varices. This is important be-
cause esophageal varices are fragile blood vessels with a
high propensity to bleed. If no varices are found, routine
screening should occur every 3 years. If small varices are
found, the frequency is increased to every 2 years. The
Child-Pugh score should also be used to evaluate for an
increased risk of complications from portal hypertension.
For those patients with medium or large varices, pri-
mary prophylaxis should be instituted. This would in-
clude use of nonselective ß-blocker therapy to decrease
portal hypertension and lessen the likelihood of bleed-
ing. The medications that are recommended are nadolol
started at 40 mg daily and increased to obtain a resting
pulse rate reduced by 25% or a heart rate of 55 beats per
minute. Alternately, propranolol can be started at 40 mg
twice daily and increased by 10 mg twice daily to obtain a
20% reduction in resting heart rate. If side effects occur,
these medications can be titrated up more slowly in order
to give patients more time to adjust.
It should be noted that these patients must remain
on lifelong pharmacologic therapy to maintain the ben-
eﬁcial effect of preventing variceal hemorrhage (Turnes
et al., 2006). Yet, many times patients with documented
esophageal varices are not on ß-blocker therapy. In the
study by Wilbur and Sidhu (2005) examining the charts
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of 106 patients with liver disease who were hospitalized
with suspected variceal hemorrhage, none were on ß-
blockers. As medical professionals we must do a better
job with this treatment protocol; as NPs our background
as patient advocates and patient educators will assist us in
teaching patients the necessity of this treatment.
Patients started on nonselective ß-blocker therapy must
be educated about potential side effects. The most com-
mon side effects include hypotension, fatigue, dizziness,
impotence, dry mouth and nausea, vomiting, diarrhea,
or constipation. If patients are started on lower doses and
titrated up slowly, these side effects will usually subside.
Patients should understand the effect of the medication
and the necessity of treatment. Patient teaching on how
to take a radial pulse will help with appropriate titra-
tion of medication. This type of educational process will
increase medication compliance. If, after educating pa-
tients and titrating slowly, the patient is unable or un-
willing to continue then the next line therapy should be
considered.
As an option for those persons who are unable to tol-
erate nonselective ß-blocker therapy, contraindicated for
nonselective ß-blocker therapy, or noncompliant with
the medication regimen, EVL is the second line treatment
plan. This is a relatively invasive procedure with the ad-
ditional concern of sedation and the accompanying risks.
Most often multiple EVL procedures are required in order
to attain eradication of varices. Still, this is a viable treat-
ment option and can reduce the risk of primary bleeding
of esophageal varices.
It is important to remember that nonselective ß-blocker
therapy may provide an added beneﬁt of reducing the in-
cidence of bacterial translocation. This process can occur
because of the decreased intestinal transit time and the
increased bacterial overgrowth that results. Patients with
portal hypertension not only have an increased risk of
developing esophageal varices, but also an increased risk
of ascites. The mere presence of ascites carries the threat
of developing spontaneous bacterial peritonitis. Because
spontaneous bacterial peritonitis also has a high mortal-
ity risk, decreasing the risk is vital.
Patients with cirrhosis should also be taught to self-
monitor for other signs of bleeding such as from por-
tal gastropathy or rectal varices. Stools should be mon-
itored for melena, hematochezia, or bright red blood per
rectum. Fatigue or dizziness should be reported as these
could be signs of occult bleeding rather than a side ef-
fect of ß-blockers. Baseline and periodic complete blood
counts should be monitored for evidence of bleeding as
well as using fecal occult blood tests, such as guaiac smear
test, for screening at each ofﬁce visit. This test can also be
prepared by the patient at home and mailed to the ofﬁce
for routine evaluation.
As the NPs caring for these patients we must also be
vigilant at reducing further injury to the liver. If the cir-
rhosis is caused by alcohol, counseling to stop or at the
very least decrease intake is imperative. If the damage
has not overwhelmed the liver, progression of the dis-
ease can be halted or slowed. For those patients who
have cirrhosis another important consideration is care-
ful screening of medications. Because many of the med-
ications taken are metabolized via the liver, doses may
need to be adjusted or an alternate medication chosen.
Through careful assessment, examination, and treatment,
these patients can effectively lessen complications and in-
crease their life span.
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